Highest-materiality recent filing
Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M
Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
Lucid Diagnostics closes $18M underwritten offering of 18M shares at $1.00/share
Closed sale of 18,000,000 shares at $1.00/share; gross proceeds $18M, net proceeds ~$16.8M.
Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share
Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.
Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded
Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
Lucid Diagnostics closes $28.75M public offering of 28.75M shares at $1.00/share
Closed underwritten public offering of 28,750,000 shares at $1.00 per share, including full exercise of underwriters' option for 3,750,000 additional shares.
Lucid Diagnostics prices $25M public offering of 25M shares at $1.00 per share
Priced 25,000,000 shares of common stock at $1.00 per share; gross proceeds ~$25M before expenses.
Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering
Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
Lucid Diagnostics enters $25M ATM equity offering with Maxim Group
Up to $25M of common stock may be sold at-the-market via Maxim Group as agent.
Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity
Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
Lucid Diagnostics prices $15M public offering of 12.5M shares at $1.20 per share
Gross proceeds ~$15M from 12.5M shares at $1.20; underwriters have 45-day option for 1.875M additional shares.
Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed
Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
Lucid Diagnostics closes $15.3M registered direct offering of 13.9M shares at $1.10/share
Closed offering of 13,939,331 common shares at $1.10 per share for gross proceeds of $15.3M.
Lucid Diagnostics raises $15.3M in registered direct offering of 13.9M shares at $1.10/share
Gross proceeds of ~$15.3M from sale of 13,939,331 shares at $1.10/share; net proceeds ~$14.5M after fees/expenses.
Sold $21.95M principal amount Senior Secured Convertible Notes, net proceeds $18.3M after repaying 2023 note.
Lucid Diagnostics sells $21.75M in convertible notes to redeem existing 2023 note
Aggregate $21.75M in Senior Secured Convertible Notes sold to accredited investors.
EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
Lucid Diagnostics redeems 2023 convertible note, issues $1.00/sh 12% secured notes due 2029
Notice to redeem 2023 Senior Convertible Note at optional redemption price; payment due within 10-20 business days.
Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M
EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
Lucid Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on June 21, 2024: closing bid price below $1 for 30 consecutive business days.
Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially
EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board
Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers
EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
Lucid Diagnostics completes $18.16M Series B Preferred offering and exchange of Series A/A-1 shares
Gross proceeds of $18.16M: $12.495M from new subscriptions and $5.67M from Series A-1 sales immediately exchanged.
Lucid Diagnostics transfers Nasdaq listing to Capital Market after Global Market non-compliance
Received Nasdaq approval on Nov 27, 2023 to transfer common stock listing from Global Market to Capital Market.
Nasdaq notified Lucid of non-compliance with Global Market equity standard requiring $10M minimum equity; reported equity was $2.556M as of Sep 30, 2023.
Lucid Diagnostics raises $5.0M through sale of Series A-1 Convertible Preferred Stock
Sold 5,000 Series A-1 Preferred shares at $1,000/share to accredited investors; gross proceeds of $5.0M closed Oct 18, 2023.
MolDX publishes Medicare LCD for esophageal cancer testing; effective May 14, 2023
Foundational LCD L39256 provides criteria for future coverage of molecular tests like EsoGuard.
Lucid Diagnostics consummates $11.1M senior secured convertible note with accredited investor
Closed sale of up to $11,111,110 Senior Secured Convertible Note to an accredited investor as of March 21, 2023.
Lucid Diagnostics raises $24.6M in preferred & debt; 4Q22 revenue $0.1M, net loss $14.9M
Secured $13.6M from Series A preferred stock and $11.1M senior secured convertible note, extending cash runway into 2024.
Lucid Diagnostics raises $13.625M via sale of Series A Convertible Preferred Stock
Sold 13,625 shares of Series A Convertible Preferred at $1,000/share for gross proceeds of $13.625M.
Lucid/PAVmed cut 20% workforce, delay studies, halt products to reduce cash burn 25%
Workforce reduction of ~20% and other cost cuts aimed at lowering quarterly cash burn by at least 25%.
PAVmed elected stock for $1.65M in MSA fees (July-Sept 2022): 750,818 shares at 0.70 floor.
Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.
Effective on November 6, 2023, the board of directors (the “ Board ”) of Lucid Diagnostics Inc. (the “ Company ”) appointed Shaun M. O’Neil as the President of the Company.
appointed Debra J. White as a Class C director of the Company.
Ms. White replaces Aster Angagaw, who resigned as a director effective on July 30, 2022.
On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.
Max materiality 0.80 · Median 0.65 · Most common event other_material